145 related articles for article (PubMed ID: 37968194)
21. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.
Sato J; Ishikawa H; Hamauchi S; Yamawaki Y; Mori K; Kiyohara Y; Yoshikawa S; Yamazaki K; Yasui H; Shino M
J Oncol Pharm Pract; 2020 Mar; 26(2):361-367. PubMed ID: 31106665
[TBL] [Abstract][Full Text] [Related]
22. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Jatoi A; Ou FS; Ahn DH; Zemla TJ; Le-Rademacher JG; Boland P; Ciombor KK; Jacobs NL; Pasche B; Cleary JM; McCune JS; Pedersen KS; Barzi A; Chiorean EG; Heying EN; Lenz HJ; Sloan JA; Grothey A; Lacouture ME; Bekaii-Saab T
Oncologist; 2021 Jul; 26(7):610-618. PubMed ID: 33604969
[TBL] [Abstract][Full Text] [Related]
23. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
[TBL] [Abstract][Full Text] [Related]
24. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
[TBL] [Abstract][Full Text] [Related]
26. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
27. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.
Ono K; Murase R; Matsumoto N; Kubota Y; Ishida H; Fujita KI
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38459188
[TBL] [Abstract][Full Text] [Related]
28. Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Lu CW; Pang JS; Ko YS; Chang CJ; Wang CW; Chen WT; Chen CB; Hui RC; Hung SI; Lu LY; Lu KL; Wang CL; Wu CE; Hsu PC; Fang YF; Li SH; Ko HW; Tseng LC; Shih FY; Chen MJ; Chung WH
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):328-339. PubMed ID: 36366861
[TBL] [Abstract][Full Text] [Related]
29. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
31. [Corneal perforation with tyrosine kinase inhibitor chemotherapy: REGORAFENIB].
Lanfant L; Trone MC; Garcin T; Gauthier AS; Thuret G; Gain P
J Fr Ophtalmol; 2021 Apr; 44(4):544-548. PubMed ID: 33612324
[TBL] [Abstract][Full Text] [Related]
32. Management of regorafenib-related toxicities: a review.
Krishnamoorthy SK; Relias V; Sebastian S; Jayaraman V; Saif MW
Therap Adv Gastroenterol; 2015 Sep; 8(5):285-97. PubMed ID: 26327919
[TBL] [Abstract][Full Text] [Related]
33. Prostaglandin E
Shichiri H; Yamamoto K; Tokura M; Ishida T; Uda A; Bito T; Nishigori C; Nakagawa T; Hirano T; Yano I; Hirai M
Biochem Biophys Res Commun; 2017 Apr; 485(2):227-233. PubMed ID: 28237700
[TBL] [Abstract][Full Text] [Related]
34. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
[TBL] [Abstract][Full Text] [Related]
36. [Regorafenib approved in Metastatic Colorectal cancer].
André T; Dumont SN
Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
38. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
39. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
Fischer A; Wu S; Ho AL; Lacouture ME
Invest New Drugs; 2013 Jun; 31(3):787-97. PubMed ID: 23345001
[TBL] [Abstract][Full Text] [Related]
40. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
